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Abstract
Epigenetic regulation plays a key role in the link between inflammation and cancer. Here we examine Mbd2, which
mediates epigenetic transcriptional silencing by binding to methylated DNA. In separate studies the Mbd2−/− mouse
has been shown (1) to be resistant to intestinal tumourigenesis and (2) to have an enhanced inflammatory/immune
response, observations that are inconsistent with the links between inflammation and cancer. To clarify its role
in tumourigenesis and inflammation, we used constitutive and conditional models of Mbd2 deletion to explore
its epithelial and non-epithelial roles in the intestine. Using a conditional model, we found that suppression of
intestinal tumourigenesis is due primarily to the absence of Mbd2 within the epithelia. Next, we demonstrated,
using the DSS colitis model, that non-epithelial roles of Mbd2 are key in preventing the transition from acute
to tumour-promoting chronic inflammation. Combining models revealed that prior to inflammation the altered
Mbd2−/− immune response plays a role in intestinal tumour suppression. However, following inflammation the
intestine converts from tumour suppressive to tumour promoting. To summarise, in the intestine the normal
function of Mbd2 is exploited by cancer cells to enable tumourigenesis, while in the immune system it plays a key
role in preventing tumour-enabling inflammation. Which role is dominant depends on the inflammation status of
the intestine. As environmental interactions within the intestine can alter DNA methylation patterns, we propose
that Mbd2 plays a key role in determining whether these interactions are anti- or pro-tumourigenic and this makes
it a useful new epigenetic model for inflammation-associated carcinogenesis.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Epigenetic regulation of the genome plays a major role
in human health and disease [1]. DNA methylation,
via addition of a methyl group to the fifth carbon of
cytosine in a CpG dinucleotide [2], is a fundamental
epigenetic modification. As DNA methylation can be
influenced by the environment, it plays a large role in the
biology of diseases with a strong environmental com-
ponent, such as the intestine [3,4]. DNA methylation
is synonymous with transcriptional silencing as it can
either inhibit binding of transcription regulators, such
as c-Myc [5], or recruit co-repressor complexes that
trigger the formation of repressive chromatin [6]. These
co-repressor complexes are recruited by proteins which
bind directly to methylated DNA to mediate a cell’s
complex multi-layered transcriptional programme.
These methyl-binding proteins act as ‘master con-
trollers’ by mediating the effects of DNA methylation;
thus, they can regulate many genes simultaneously,
including aberrantly methylated genes that lead to dis-
ease [4]. One of these proteins, methyl binding domain
protein 2 (Mbd2), has been shown to play crucial roles
in various biological processes and diseases [4,7].
The importance of its role has been highlighted using
mouse models, where its deficiency has been shown to
influence intestinal inflammatory responses [8–13] and
epithelial cell biology [14–16]. These multiple roles
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potentially make it a unifying player in the myriad of
biological processes that contribute to the initiation and
development of intestinal cancer.
Using the Apc+/min model [17], we have previously
demonstrated that the Mbd2−/− mouse is resistant to
Wnt-driven tumourigenesis [15,16] – the most common
type of human colorectal cancer (CRC). Further, we
demonstrated that Mbd2 deficiency in a Wnt-activated
intestine reduces the expression of Wnt target genes,
including c-Myc [15]. Potentially, this attenuation of
tumourigenesis is due to a lack of Mbd2-dependent
silencing of tumour suppressor genes; however, the
mechanism of Apc+/minMbd2−/− tumour suppression
remains unknown. During the course of these studies,
we reported that Mbd2 deficiency in Wnt-activated
intestinal epithelia relieved silencing of genes associ-
ated with immune responses [15]. This is in accordance
with previously reported roles for Mbd2 in guiding
cells down the different epigenetically regulated T-cell
lineages [8–13]. This presents within the intestine of the
Mbd2−/− mouse as an excessive type 1 response upon
immune challenge [8], characterised by an increase
in the expression of the pro-inflammatory cytokine
interferon gamma (Ifng). Evidence from mice and
humans suggests an anti-tumourigenic role for Ifng in
colorectal cancer (CRC), as a loss of type 1 cytokines
accompanies the adenoma–carcinoma sequence in the
colorectum [18]; intestinal tumourigenesis is promoted
in mice deficient for Ifng or its receptors [19]; and Th1
cytokines lead to cancer senescence [20]. This role is
due, at least in part, to Ifng-mediated c-Myc inhibi-
tion [21,22] and increased expression of the HLA-DR
antigen [21] – features we previously reported in the
Wnt-activated Mbd2-deficient intestine [21]. However,
in its inflammatory role, Ifng is causally involved in
inflammatory bowel diseases, where chronic inflam-
mation drives cellular and molecular inflammatory
mechanisms that underlie tumour initiation [23,24].
Evidence from other tissues indicates that the tussle
between the anti- and pro-tumourigenic functions of
Ifng seems to be dependent on the contexts of tumour
specificity, microenvironmental factors, and signalling
intensity [25].
Here we examine how the increased inflammatory
response and tumour suppression phenotype interact in
the Mbd2-deficient mouse intestine. Our findings high-
light separate roles for Mbd2 in controlling intestinal
inflammation and enabling epithelial tumourigenesis.
Materials and methods
Animal models
All animal procedures were conducted in accordance
with institutional animal care guidelines and UK Home
Office regulations. In brief, mice were maintained
in a specific pathogen-free (SPF) barrier facility in
conventional open top cages on Eco-Pure Chips 6
Premium bedding (Datesand, Manchester, UK) under a
12 h light cycle, with IPS 5008 diet (Labdiet-IPS Ltd,
London, UK) provided for nutritional support. To enrich
the environment, irradiated sunflower seeds (at weaning
only), Techniplast mouse houses (Techniplast, Leices-
ter, UK), and small chewsticks (Labdiet-IPS Ltd) were
provided. All mice were from a mixed background and
were homozygous with respect to the C57Bl/6 Pla2g2a
(also called Mom-1) allele. Experimental animals were
between 10 and 15 weeks old, with siblings used as
controls. The alleles for Ah-cre [26], Apc+/min, Ifng−/−
[27], Lgr5creERT2 [28], Mbd2−/− [9], Mbd2flx/flx [13],
and vil-creERT2 [29] have been described previously.
Induction of the Ah-cre transgene was performed by
administering three intraperitoneal (i.p.) injections of
β-naphthoflavone (BNF; Sigma, Gillingham, Dorset,
UK) at 80 mg/kg in a 24 h period. Induction of the
Lgr5creERT2 and vil-creERT2 transgenes was achieved
by administering a single injection of tamoxifen (TAM;
80 mg/kg i.p.; Sigma) for four consecutive days. For
induction of colitis (acute inflammatory insult), mice
were given dextran sodium sulphate (MW 36 000–50
000; MP Biomedicals, Fisher Scientific, Loughborough,
UK) ad libitum in drinking water at the concentration
(w/v) and duration stated. Colitis disease severity
was measured according to published protocols [30].
For survival analysis, mice were harvested at either
a specific time point or a humane endpoint when
mice displayed phenotypes indicative of acute colitis
(weight loss and diarrhoea) or tumour burden (pale
feet, bloating, prolapse or piloerection). Tumour burden
was measured at point of death by removing the entire
intestine and mounting en face in methacarn fixative
(4:2:1 methanol, chloroform, and glacial acetic acid)
to determine the number of macroscopic lesions and
their size.
Reverse transcription–quantitative PCR (RT-qPCR)
analyses
The following methods were performed according
to the manufacturer’s instructions unless otherwise
stated. For analysis of gene expression in the intestine,
three to five mice from each control and experimental
group were harvested. RNA was extracted either from
a 0.5 cm portion of the whole large intestine taken ∼1
cm distally from the caecum or from crypt epithelia
extracted from the whole large intestine; samples were
stored at −80∘C in RNAlater (Sigma, Dorset, UK) [31].
Total RNA was extracted using the RNeasy kit (Qiagen,
Manchester, UK) and DNase-treated using the Turbo
DNase kit (Fisher Scientific). Complimentary DNA
(cDNA) was reverse transcribed from 1 μg of RNA
using random hexamers (Promega, Southampton, UK)
and the Superscript III kits (Fisher Scientific, Lough-
borough, UK). For relative quantitation, all samples
were run in duplicate on the StepOnePlus PCR machine
using Fast SYBR Green master mix (Applied Biosys-
tems, Oxford, UK) or Taqman Universal Mastermix
II (Fisher Scientific). The threshold cycle (Ct) values
of each gene analysed were normalised to a reference
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gene. For expression analysis, Ct values were nor-
malised against the Actb gene (mouse) or RPL37A
(human). Oligonucleotide sequences used for relative
quantification are available upon request. Differences
between groups were assessed using the 2−ΔΔCT
method [32]. Two-tailed Mann–Whitney U (MW)
tests were performed on the ΔCt values and differ-
ences with P values less than 0.05 were considered
significant [33].
Reporter visualization, immunohistochemistry
(IHC), and cellular analysis
For IHC, tissuewas fixed in ice-cold 10%neutral sodium
phosphate-buffered formalin (Sigma) and processed into
wax blocks by conventional means. Section were cut at 5
μm thickness, dewaxed, and rehydrated into PBS. Stain-
ing was performed using the Envision+ mouse or rab-
bit kit (Dako, Agilent Ltd, Stockport, UK) according to
the manufacturer’s instructions. To identify cells which
had lost Apc, we used nuclear β-catenin as a surrogate
marker, using a mouse monoclonal anti-β-catenin anti-
body (Cat No 610154; BD Biosciences, Wokingham,
UK) at 1:200. For Paneth cell detection, we used a rab-
bit polyclonal anti-lysozyme antibody (Cat No RB-372;
Neomarkers/Labvision, Fisher Scientific) at 1:200. CD4
cells were stained with a mouse anti-CD4 antibody
(Clone 4sm95; eBioscience, Fisher Scientific; 1/50). To
visualize mucin and goblet cells, slides were stained
with Alcian Blue. The cells between the base of the crypt
and the junction with the villus were designated as the
proliferative zone. Cellular analysis was performed on
more than 25 whole crypts from at least three mice of
each genotype. Slides were scanned for analysis using
the Axioscan Z1 slide scanner (Zeiss, Cambridge, UK)
and images were excised from scans using the Zeiss
Axioscan Zen software.
T-cell analysis
To label the Th1 and Th2 cytokines in serum, we
used a Cytometric Bead Array Mouse Th1/Th2/Th17
Cytokine kit (BD Biosciences) following the manufac-
turer’s instructions and using a FACS Canto II (BD Bio-
sciences). To characterize the immune cell populations,
single cell suspensions of lymphocytes were prepared
from large intestine lamina propria [34,35]. Lympho-
cytes were stimulated for 4 h using ionomycin, phor-
bol myristate acetate (Sigma), and 1 μg/ml Golgistop
(Sigma). Prior to flow cytometry, lymphocytes were
stained with fluorescent conjugated antibodies against
CD4 (RM-4-5, 1/800), Ifng (XMG1.2, 1/200), IL-13
(eBIO 13a, 1/200), TCRa/b (MR5.2, 1/200) (all Fisher
Scientific), CD45 (30-F11, 1/200), CD8 (53-6.7, 1/200),
IL-4 (11B11, 1/200) (all Biolegend, London, UK), IL-17
(TC11-18H10.1, 1/100) and TNF (MP6-XT22, 1/200)
(both BD Biosciences), and a live/dead marker. Data
were analysed using FCAPArray v3.0 (BDBiosciences)
and FlowJo (FlowJo LLC, Ashland, OR, USA) software.
Statistical analysis was performed using three to five ani-
mals per genotype and three independent experiments.
Significance was calculated using a three-way full fac-
torial fit model and a joint F-test to assess the effects of
genotype, treatment, and experiment day on the cytokine
response [36].
Statistical analysis
All preclinical data were evaluated with GraphPad
Prism software, version 7.02 (GraphPad, La Jolla, CA,
USA). When two variables were compared, a two-tailed
Mann–Whitney test was performed. Survival data were
analysed using the Kaplan–Meier test. The relationship
between genotype and phenotype was assessed using
Fisher’s exact test. If not indicated otherwise, the statis-
tical mean is presented and error bars represent SEM.
On graphs, P values are indicated as follows: *p < 0.05;
**p < 0.01; ***p <0 .001.
Results
Intestinal epithelial loss of Mbd2 is sufficient
to suppress tumourigenesis
Potentially, the intestinal tumour resistance of the
Mbd2−/− mouse is due to an enhanced anti-tumourigenic
Th1/Ifng response, a loss of Mbd2 epigenetic regula-
tion within the intestinal epithelia or a combination of
both. To clarify this situation, we utilised a conditional
Cre-Lox mouse to deleteMbd2 solely within the intesti-
nal epithelia, allowing us to establish the epithelial
contribution of Mbd2 to tumourigenesis. Mice carrying
the Ah-cre and Mbd2ex1 transgenes were crossed to
generate Ah-creMbd2ex1/ex1 mice, which following BNF
induction deleted exon 1 of Mbd2 specifically within
the crypts of the intestinal epithelia. Cohorts of four
to six mice were examined 4 days after deletion. In
comparison to control cohorts, there was no alteration
to the expression of Wnt target genes (c-Myc and
Axin2), the size of the crypt proliferative zone, Paneth
cell localisation (Figure 1A–C) or genes characteristic
of the differentiated cell types (supplementary mate-
rial, Figure S1). To investigate the epithelial role of
Mbd2 in Wnt signalling, Ah-creMbd2ex1/ex1 mice were
crossed to mice carrying an Apcflx allele, to generate
Ah-creApcflx/flxMbd2ex1/ex1 and control cohorts. Upon
Ah-cre-driven Apc loss, we observed an upregulation
of Wnt target genes, an increase in the size of the crypt
proliferative zone, and mislocalisation of Paneth cells
(Figure 1A–C), as we have previously reported [37].
In comparison, the increase in expression of Wnt target
genes Axin2 (p = 0.0159) and c-Myc (p = 0.0159),
due to Apc deletion, was significantly attenuated by
additional loss of Mbd2 (p = 0.0159) (Figure 1A).
This corresponded with a decrease in the size of
the proliferative zone within the crypts of Leiberkühn
(Figure 1B) and a partial rescue of the mislocalisation of
Paneth cells (a characteristic of Ah-cre-driven Apc loss)
(Figure 1C). These findings are consistent with our pre-
viously reported data using the Ah-creApcflx/flxMbd2−/−
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 270–282
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model [15], in which Mbd2 is absent systemically.
To investigate whether these changes would influence
the initiation of intestinal tumourigenesis, cohorts of
Ah-creApc+/flx (N = 20) and Ah-creApc+/flxMbd2ex1/ex1
(N = 23) mice were induced at 10–12 weeks of age and
harvested at 180 days post-induction (dpi). These mice
are equivalent to the Apc+/min model, as they require the
spontaneous loss of the remaining wild-type allele for
tumour initiation. The Ah-creApc+/flxMbd2 ex1/ex1 cohort
showed a significant increase in survival compared with
the Ah-creApc+/fl control cohort (Figure 2A). Expres-
sion analysis on the whole intestine from six to eight
animals within each cohort confirmed the continued
absence of Mbd2 within the epithelia (Figure 2B). At
180 dpi, the Ah-creApc+/flxMbd2ex1/ex1 cohort had sig-
nificantly fewer tumours and reduced burden compared
with the control cohort (Figure 2C). In summary, the
absence of Mbd2 within the intestinal epithelia is well
tolerated and sufficient to suppress Wnt signalling and
tumourigenesis, replicating the phenotype observed
in the Apc+/minMbd2−/− mice and demonstrating a
cell intrinsic mechanism for Mbd2. We next sought
to investigate the role that Mbd2 plays in intestinal
inflammation.
Mbd2 deficiency exacerbates DSS-induced colitis
As previous reports demonstrated that theMbd2−/− mice
have an enhanced CD4+ T-helper type 1 response, char-
acterised by an increase in Ifng levels, we first sought to
verify this in our mice [8,9]. Lymphocytes were isolated
from the large intestine lamina propria of wild type
(WT) and Mbd2−/− mice and characterised using flow
cytometry. The Mbd2−/− mice displayed a significant
increase in the numbers of CD4+Ifng+ (Figure 3A) and
CD8+cells expressing IL-4, IL-17, Ifng, and TNF, with
CD8+ cells also displaying increased expression of
IL-13 (Figure 3A, B), similar to previously published
data [8]. The significantly elevated Ifng levels were
further confirmed by an increase in mRNA expression
and Ifng presence in the serum (supplementary mate-
rial, Figure S2A, B). To investigate the impact of these
changes on the large intestine, cohorts of ≥ 6 mice were
administered 2%DSS (w/v) in drinking water ad libitum
for 6 days to induce acute inflammation; experiments
were repeated three times to assess reproducibility. The
Mbd2−/− mouse demonstrated a significant increase
in the disease activity index (DAI), histology score,
weight loss, and large intestine atrophy compared with
control mice (Figure 3C and supplementary material,
Figure S2C–E). Analysis of lymphocytes from the
lamina propria indicated an altered cytokine profile
with a significant increase in CD4+ cells positive for
IL-17, Ifng, TNF, and CD8+Ifng+ cells (Figure 3B, D).
As a key role for CD4+ cells and Ifng in DSS-induced
colitis has been previously shown, we repeated this
experiment using Ifng−/− mice and neutralising CD4+
antibodies to determine their contribution to the phe-
notype. The absence of Ifng suppressed colitis, as
previously shown [38], and significantly decreased
severity in the Mbd2−/−Ifng−/− double-knockout mice
(Figure 3C). To address the importance of the CD4+
lymphocyte population, Mbd2−/− and control mice
were administered a CD4 neutralising antibody −3,
−1, and 0 days prior to induction of acute inflam-
mation. The blockade of CD4+ cells reduced the
DAI and weight loss scores to the levels previously
observed by deleting Ifng (Figure 3C). To investigate
whether the epithelial loss of Mbd2 played a role in
the altered immune response, we generated cohorts
of vil-creERT2Mbd2ex1/ex1 to drive Mbd2 deletion in
the large intestinal epithelia. Four days after deletion
of Mbd2, mice were exposed to 2% DSS in drinking
water ad libitum. Six days following DSS exposure, the
vil-creERT2Mbd2ex1/ex1 mice, in comparison to control
mice, displayed a significant four-fold decrease inMbd2
expression within the large intestine crypt epithelia but
no difference in overall disease severity (supplementary
material, Figure S3A, B). Further expression analysis
within the large intestine indicated no alteration to
genes characteristic of Th1 (Ifng), Th17 (Tbx21), and
Tregs (Foxp3), which we previously demonstrated
to be altered in the Mbd2−/− setting [8,10,12] (sup-
plementary material, Figure S3C). In summary, the
Mbd2−/− mouse is highly susceptible to DSS-induced
colitis, at least in part, due to the loss of Mbd2 func-
tion specifically within the CD4+ cells and loss of
appropriate regulation of the pro-inflammatory cytokine
Ifng. However, additional roles for Mbd2 within the
non-epithelial cells of the stromal compartment cannot
be discounted due to the epithelial specific nature of
the vil-creERT2 model. We next sought to establish
the role of this inflammation susceptibility in a cancer
setting.
DSS exposure leads to chronic mucosal colitis
and tumourigenesis in the Mbd2−/− mouse
To determine whether this increased susceptibility
to colitis had a long-term effect on intestinal health,
cohorts of control and Mbd2−/− mice were admin-
istered 2% DSS for 6 days ad libitum and aged for
30, 60, and 170 days. The control Mbd2+/+ litter-
mates made a complete recovery following withdrawal
of DSS and at 30 (N = 9) and 170 days (N = 11)
post-inflammation showed no sign of intestinal disease
(Figure 4A). In contrast the Mbd2−/− mice failed to
resolve the inflammation and developed a chronic
mucosal colitis. At 30 days, 83% (5/6, p = 0.002) of
Mbd2−/− mice showed continuing signs of colitis which
included severe mucosal inflammation with severe
diarrhoea, widespread crypt loss, superficial ulceration,
focal active cryptitis with scattered crypt abscesses,
and patches of epithelial regeneration (Figure 4B and
supplementary material, Figure S4A). At 60 days, the
severe diarrhoea and bleeding had subsided in all mice
(N = 6); however, in the intestines of 66% (4/6) of
these mice, an active chronic mucosal colitis remained,
with a mononuclear cell infiltrate in the lamina propria,
distortion of crypt architecture, regenerative epithelial
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Figure 1. Epithelial loss ofMbd2 in the intestine attenuates the phenotype associated with Ah-creApc deletion. (A) RT-qPCR gene expression
data indicating thatMbd2 loss suppresses the expression of Wnt target genes following Apc deletion (N = 4–6). (B) Quantification of crypt
size (left panel) indicating reduction in the size of the proliferative zone and representative images of the proliferative zone and Paneth
cells (brown; right panel). (C) Cumulative frequency curve of Paneth cell localisation within the intestinal crypt, indicating partial rescue of
positioning in the Ah-creApcflx/flxMbd2ex1/ex1 intestine compared with Ah-creApcflx/flx .
hyperplasia, and crypt fission (supplementary material,
Figure S4B). At 170 dpi, 60% (6/10, p = 0.0039) of
the mice had flat lesions which were classified as muci-
nous adenocarcinoma (Figure 4C and supplementary
material, Figure S4C). These lesions displayed nuclear
β-catenin staining indicating that they were driven via
deregulation of the Wnt pathway (Figure 4D and sup-
plementary material, Figure S4C). We have previously
shown that absence of Mbd2 in the epithelia alone
is not sufficient to alter the acute immune response
(supplementary material, Figure S3B). To confirm there
was not a longer-term phenotype, we generated cohorts
of vil-creERT2Mbd2ex1/ex1 mice for analysis. At 180
days following exposure to 2% DSS in drinking water
given ad libitum, these mice, in contrast to the systemic
Mbd2−/− setting, showed no signs of intestinal disease
(data not shown). These data suggest that the switch
to a tumour-promoting environment is dependent on
loss of Mbd2 in cells outside of the intestinal epithelia,
with the cells of the immune system being the most
likely candidates. We next sought to establish the
effect of the Mbd2−/− inflammatory response on the
tumour suppression observed in the Apc+/minMbd2−/−
intestine.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 270–282
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Figure 2. Mbd2 deficiency within the intestinal epithelia protects against Wnt-driven tumourigenesis. (A) Kaplan–Meier survival curve
indicating enhanced survival following epithelial loss of Ah-creApcflx/flxMbd2ex1/ex1 [N = 23, p = 0.005; log-rank (Mantel–Cox) test]
compared with Ah-creApcflx/flx (N = 20). (B) RT-qPCR expression analysis for Mbd2 expression 180 dpi after Ah-cre induction indicates
significant downregulation in Ah-creApcflx/flxMbd2ex1/ex1 mice (N = 4–6). (C) Analysis of tumour number (left panel) and burden (mm2;
right panel) in surviving mice at 180 dpi indicates a significant decrease in the Ah-creApcflx/flxMbd2ex1/ex1 cohort.
Chronic inflammation overcomes Apc+/minMbd2−/−
intestinal tumour suppression
As the Apc+/minMbd2−/− is resistant to intestinal
tumourigenesis, we addressed whether this is still
the case following an acute inflammatory insult.
Apc+/minMbd2−/− mice at 10–12 weeks old were
exposed to 2% DSS (w/v) for 6 days and allowed to age
for 30 and 180 days. At 30 days after DSS withdrawal,
all Apc+/minMbd2−/− mice (4/4) still presented with
chronic colitis (Figure 5A). At 180 days post-DSS, 72%
(8/11) of Apc+/minMbd2−/− mice displayed mucinous
adenocarcinoma with nuclear β-catenin (Figure 5B),
in contrast to control Apc+/minMbd2−/− mice, which
remained disease-free at the same age, as reported
previously [16]. These lesions presented as flat tumours
in contrast to the standard polypoid-type lesions with
extensive nuclear β-catenin that developed in the
Apc+/min model (Figure 5C). Thus, following the onset
of a chronic inflammatory response, tumour suppression
is lost in the Apc+/minMbd2−/− large intestine; indicat-
ing that the protection afforded by the absence of
Mbd2 in the epithelia is overcome following the onset
of an Mbd2-deficient inflammatory response in the
intestine.
Loss of Mbd2 decreases the survival
of Apc-deficient stem cells
Comparison of the data from our Ah-creApc+/flx
Mbd2ex1/ex1 mice and our previously published
Ah-creApcflx/flxMbd2−/− [15] and Apc+/minMbd2−/−
[16] mice indicated that the suppression of tumouri-
genesis, Wnt activation, and Paneth cell relocalisation
phenotypes were enhanced in the Mbd2−/− mouse.
These data suggested that in the Mbd2−/− model the
epithelial and non-epithelial phenotypes synergised to
suppress tumourigenesis. As we have demonstrated a
significant role for Ifng in the Mbd2−/− inflammatory
response and it is a key player in inflammation and
anti-tumour immune responses [18,20,21,23,39,40], we
sought to assess the relevance of Ifng in the tumour
suppression observed in Apc+/minMbd2−/− mice. We
generated Apc+/minMbd2−/−Ifng−/− mice to explore
whether loss of Ifng impacted on intestinal tumour
suppression. As expected, at 60 days, the Apc+/min
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 270–282
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Figure 3. Mbd2 deficiency increases susceptibility to chronic intestinal inflammation. (A) Flow cytometry plots illustrating an increase in
CD4+Ifng+ cells following PMA stimulation in Mbd2−/− mice in comparison to WT. (B) Bar charts quantifying the cytokine expression
profiles of CD4 and CD8 lamina propria lymphocytes as a percentage of the parent population in WT and Mbd2−/− mice before and after
DSS exposure. (C) Bar chart illustrating the DAI score 6 days after addition of 2% DSS to drinking water. (D) WT (left panel) and Mbd2−/−
(right panel) large intestine sections illustrating crypt loss and an increase in CD4+ cell number (brown) following DSS exposure.
(N = 6) mice displayed significantly more nuclear
β-catenin-positive lesions (average 22) in comparison
to the Apc+/minMbd2−/− mice (N = 6; average < 1)
(Figure 6A). As we have previously demonstrated that
epithelial loss of Mbd2 alone is capable of intestinal
tumour suppression (Figure 1), it is of note that the
Apc+/minMbd2−/−Ifng−/− mice (N = 6) displayed a small
but significant increase in nuclear β-catenin-positive
lesions (p = 0.03; average 2.6), indicating that in the
absence of Ifng a small number of lesions can escape
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Figure 4. Mbd2−/−-driven inflammation drives tumourigenesis in the large intestine. (A) Scoring for the presence of intestinal disease,
following DSS withdrawal, indicating the percentage of mice with a histologically normal large intestine at different time points following
exposure. d = days. (B) Representative image of Mbd2−/− intestine 30 days post-inflammation displaying a chronic mucosal colitis with
superficial ulceration (↓) and mononuclear infiltrate (→). (C)Mbd2−/− intestine 170 days post-inflammation displaying an adenocarcinoma
stained for mucin (blue). (D) Mbd2−/− mucinous adenocarcinoma displaying heterogeneous nuclear β-catenin (brown,→; inset).
the tumour resistance conferred by epithelial Mbd2
loss. In our previous work, where we investigated mice
4 days after acute Apc loss in the crypts of Mbd2−/−
mice, this information may have been obscured [15].
This acute Apc loss does not reflect the small number
of mutated cells which initiate an individual tumour
in vivo and presents over an insufficient time for an
adaptive immunological anti-tumorigenic phenotype to
manifest. To overcome this, we targeted gene deletion
to the intestinal stem cell (ISC) using the Lgr5cre
transgene to generate Lgr5creERT2Apcflx/flxMbd2flx/flx
and Lgr5creERT2Apcflx/flxMbd2−/− mice. These allowed
us to delete Apc specifically within a proportion
of ISCs, the cell of origin for CRC [41], allowing
us to observe the effects of Mbd2 deficiency on
Apc-deleted ISCs over a longer (15-day) time frame.
In comparison to the control Lgr5creERT2Apcflx/flx
(N = 6) mice, we observed a significant reduction
in the number of nuclear β-catenin lesions in the
Lgr5creERT2Apcflx/flxMbd2ex1/ex1 (N = 7) cohort, which
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Figure 5. Inflammation overcomes the tumour resistance in
the Apc+/minMbd2−/− intestine. (A) Representative image of
Apc+/minMbd2−/− intestine 30 days post-inflammation displaying
a chronic mucosal colitis with large abscess (↓) and mononu-
clear infiltrate (→). (B) Apc+/minMbd2−/− intestine 180 days after
onset of inflammation displaying a flat mucinous adenocarci-
noma (left panel) with heterogeneous nuclear β-catenin (→; right
panel). (C) Adenoma from an Apc+/min large intestine 180 days
post-inflammation displaying mucin-filled pockets (→) and exten-
sive nuclear β-catenin (brown).
was further reduced in the Lgr5creERT2Apc+/flxMbd2−/−
(N = 6) cohort (Figure 6B–D and supplementary
material, Figure S5A–C). Potentially, the increased
reduction of lesions in the Mbd2−/− mouse is due
to synergy between the enhanced anti-tumourigenic
Th1/Ifng response and the loss of Mbd2-mediated
transcriptional silencing in the ISC. However, a role
for other cells within the Mbd2−/− mouse cannot be
excluded with this system.
MBD2 loss is a rare event in colorectal cancer
Our data presented here and previously [15,16] support
the notion that in murine intestinal epithelium Mbd2 is
required to permit intestinal tumourigenesis. To investi-
gate the relevance of MBD2 in human intestinal cancer,
we looked for evidence that it is preferentially retained
in colorectal cancer, and whether its loss is associated
with a positive prognosis. To achieve this, we exam-
ined MBD2 expression in a panel of human intestinal
tumours (TNM stage I–IV, N = 7 per stage). Expres-
sion analysis failed to detect any loss or alteration to the
MBD2 profile across the different tumour stages (sup-
plementary material, Figure S6).We also examined pub-
licly available colorectal cancer sequencing data using
cBioPortal (http://www.cbioportal.org). In silico analy-
sis indicated that the MBD2 gene was classed as deep
deleted in 6/2079 (0.28%) patients; while supportive of
a role for MBD2 in enabling tumourigenesis, the small
number of samples in which MBD2 was lost prevented
any conclusive survival analysis.
Discussion
Based on these preclinical data, the genes transcrip-
tionally regulated by Mbd2 within the immune system
and stem cells from the normal and diseased intestinal
epithelia offer a set of targets that play a key role
in linking epigenetic changes to cancer. The finding
that within the intestinal epithelia normal function of
Mbd2 is required to permit tumourigenesis is supported
by clinical data; CRC sequencing data and a small
study looking specifically at MBD2 status [42] indicate
that loss of MBD2 is a rare event in CRC patients
[43,44]. However, assigning a crucial role to a gene that
requires no alteration to elicit a tumourigenic function is
extremely difficult and emphasises the value of this type
of preclinical research. Which of the Mbd2 regulated
genes within the intestinal epithelia are responsible for
this protection remains to be established. However, it is
now clear that the broad role of Mbd2 in the immune
system influences Apc-deficient epithelial stem cells.
Evidence is now emerging that cross talk between
Th cells and MHC II-expressing ISCs regulates ISC
numbers and differentiation status [45]. Recent work
has demonstrated a key role for two inflammatory
cytokines, Ifng and Tnf, and the JAK/STAT-1 signalling
pathway in the reserve ISC regenerative response
to acute intestinal inflammation [46]. Thus, the role
of Mbd2 in controlling the CD4 and Ifng immune
response is likely to be of great interest because
‘tumour-promoting inflammation’ is now identified as
an enabling characteristic in the hallmarks of cancer
[47]. Further investigation of Mbd2 functions should
aid at understanding the links between a type 1 acute
inflammatory response (the DSS-induced colitis model;
Figure 2A) and an anti-tumour response. Potentially,
in the early stages, the acute Th1–Ifng inflammatory
response in the Mbd2−/− mouse is associated with
tumour clearance. In humans, a Th1–Ifng response is a
characteristic of cancer immune surveillance [48], asso-
ciated with Th1 CD4+ and CD8+ T cells which directly
regulate tumour cell cytotoxicity or induce senescence,
while indirectly polarizing innate immune cells towards
tumour suppression [20,49]. However, the inability of
theseMbd2−/− mice to resolve the inflammation, result-
ing in chronically inflamed intestines, despite irritant
withdrawal, suggests either an auto-immune response
to a self-antigen, a neo-antigen generated by the altered
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Figure 6. Mbd2 promotes the survival of Apc-deficient stem cells. (A) Scoring of nuclear β-catenin-positive lesions indicates that at
60 days there is a reduction in Apc+/min-driven lesions due to Mbd2 deficiency which is partially dependent on Ifng (Apc+/min, N = 6;
Apc+/minMbd2−/−, N = 6; and Apc+/minMbd2−/−Ifng−/−, N = 6). (B) Following deletion of Apc in the ISC, using the Lgr5creERT2Apcflx/flx (N =
5) model, the number of nuclear β-catenin-positive crypts in the small (left panel) and large (right panel) intestine is significantly reduced
in Lgr5creERT2Apcflx/flxMbd2flx/flx mice and further reduced in the Lgr5creERT2Apcflx/flxMbd2−/− (N = 4) setting. (C) Representative image of
nuclear β-catenin-positive crypts (arrows; brown) in the small intestine 15 days after Lgr5creERT2Apcflx/flx-driven Apc deletion in ISCs and
(D) in combination with Mbd2ex1/ex1 deletion.
transcriptional profile [50], or a response to bacterial
translocation as a result of impaired epithelia integrity
[51]. This chronic pro-tumourigenic inflammatory
environment is akin to the inflammation-associated can-
cer that develops in Crohn’s and other colitis patients.
In our mouse model, the inflammation can override
the Mbd2-deficient-dependent anti-tumour suppression
mechanism to such an extent that Apc+/minMbd2−/−
mice develop adenocarcinomas, which are rarely, if
ever, seen in this model without an inflammatory insult.
This loss of inflammatory control is potentially due to
the known role of Mbd2 in promoting T-reg cell func-
tion [10]. These cells suppress the immune responses
of other cells and maintain self-tolerance; experimental
depletion of these cells in animal experiments leads to
colitis, whereas in CRC patients their accumulation is
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associated with progression [52]. Thus, Mbd2 function
may play a significant role in the progression from a pro-
tective acute response to a chronic tumour-promoting
environment.
This work highlights the role that epigenetics plays in
the cells of a tumour and its environment. These changes
can affect the tumour itself and the delicate balance
between acute and chronic inflammation which elicits
anti- or pro-tumourigenic effects. Taking into consider-
ation that in excess of 95% of CRC cases are sporadic,
arising in individuals with no identified genetic predis-
position [53], demonstrates that the aetiology of CRC
is multifactorially linked to genetic mutations, diet,
inflammatory processes, ageing, and, more recently, the
gut microbiota. The study of the epigenetic mechanisms
which underpin these gene–environment interactions
is crucial to understand how to prevent and control this
disease. Epigenetic regulation, via DNA methylation,
is commonly used by all normal cells to ensure proper
regulation of gene expression and stable gene silencing,
and is invariably altered in tumourigenesis. Recent tech-
nological advances are now leading to the identification
of new genes and loci associated with inflammatory
bowel diseases and CRC, based on generating methy-
lome maps [54,55]. However, concentrating solely on
the DNA methylome within the intestinal epithelium
neglects the fact that the majority of the CRC-associated
factors impact on the epigenome within the entire body
and not just the intestinal epithelium. Ultimately, inter-
preting the DNA methylation changes will require a
more holistic approach to explain the links between the
environment and CRC. We can begin to move towards
this goal by exploiting existing knowledge of how
DNA methylation is interpreted. The myriad of DNA
methylation differences observed at an organism level
are interpreted by a relatively small number of proteins
[4]. Given the small number of proteins capable of
interpreting the DNA methylation signal, it stands to
reason that some will play a major role in the multiple
changes that occur to permit tumour initiation and pro-
gression. In this study, we have demonstrated how loss
of a single gene involved in the interpretation of DNA
methylation has pleiotropic effects on inflammation and
cancer that could be environmentally regulated. In the
context of understanding the relationship between the
multiple factors associated with CRC, this emphasises
that non-cell intrinsic epigenetic changes beyond the
target tissue should be considered in the attempt to
unravel mechanisms.
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Supplementary figure legends
Figure S1. Expression analysis of intestine 4 days after epithelial Mbd2 deletion indicates that cell homeostasis is maintained
Figure S2. Deficiency of Mbd2 increases Ifng levels and enhances DSS-induced colitis
Figure S3. Intestinal DSS response is unaltered following vil-creERT2-driven epithelial loss of Mbd2
Figure S4. Following an acute inflammatory insult, the Mbd2-deficient intestine develops chronic mucosal colitis (6 days post-DSS administration)
Figure S5. Mbd2 promotes the survival of Apc-deficient stem cells
Figure S6. MBD2 expression is constant irrespective of intestinal tumour stage
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